Welcome to our dedicated page for Akebia Therapeut news (Ticker: AKBA), a resource for investors and traders seeking the latest updates and insights on Akebia Therapeut stock.
Akebia Therapeutics, Inc. develops and commercializes therapeutics for people impacted by kidney disease. Company news commonly covers Vafseo® (vadadustat), an oral HIF-PH inhibitor indicated for anemia due to chronic kidney disease in adults receiving dialysis, and Auryxia® (ferric citrate), a U.S.-marketed therapy for chronic kidney disease-related conditions.
Recurring updates also address product revenue, dialysis-market access, clinical data publications, and kidney disease pipeline programs, including praliciguat in focal segmental glomerulosclerosis, AKB-097 in rare kidney diseases, and AKB-9090 for cardiac surgery-associated acute kidney injury. Akebia also reports Nasdaq inducement grants, board changes, investor presentations, and quarterly financial results.
Akebia (Nasdaq: AKBA) reported Q1 2026 results: Vafseo net product revenues $15.8M, total net product revenues $52.0M, and total revenues $53.5M. Patients on Vafseo rose ~60% vs Q4 2025 and prescribers reached ~1,025 (+28%). Company reiterated pipeline progress with praliciguat Phase 2 enrollment and planned AKB-097 and AKB-9090 studies.
Q1 net loss was $9.1M, COGS rose to $12.3M driven by inventory write-downs, and cash was ~$162.6M with a stated runway of at least two years.
Akebia Therapeutics (Nasdaq: AKBA) granted inducement stock options to seven newly hired employees on April 30, 2026, totaling 208,800 shares.
The options carry an exercise price of $1.38 per share (equal to the closing price on the grant date), vest over four years (25% after one year, then quarterly), and have a 10-year term, granted under Nasdaq Listing Rule 5635(c)(4).
Akebia Therapeutics (Nasdaq: AKBA) announced publication in the Journal of the American Society of Nephrology of a post‑hoc win statistics analysis from the global Phase 3 INNO2VATE program.
The analysis found a statistically significant improvement for vadadustat versus darbepoetin alfa on a hierarchical composite of all‑cause mortality and hospitalization in dialysis‑dependent CKD patients; the analysis covered all randomized patients who received at least one dose. Vafseo (vadadustat) is approved for adults on dialysis and has been available in the U.S. since January 2025.
Akebia Therapeutics (Nasdaq: AKBA) will release first-quarter 2026 financial results for the period ended March 31, 2026, on Thursday, May 7, 2026, before market open. A conference call to discuss results and recent business highlights is scheduled for May 7, 2026 at 8:00 a.m. EDT, with a live webcast and archived replay available via the Investors section of Akebia's website.
Akebia Therapeutics (Nasdaq: AKBA) announced dosing of the first participants in a Phase 1 randomized, double-blind, placebo-controlled SAD/MAD trial of AKB-9090, an IV HIF-PH inhibitor for cardiac surgery-associated acute kidney injury (AKI).
The study will enroll up to 70 participants, assess safety, tolerability, pharmacokinetics and pharmacodynamics, and Akebia plans to report topline data in early 2027. Akebia also noted other kidney programs: praliciguat (Phase 2) and AKB-097 (Phase 2 planned H2 2026).
Akebia Therapeutics (NASDAQ: AKBA) announced that CEO John P. Butler, CFO/Chief Business Officer Erik Ostrowski, and CMO Dr. Steven Burke will hold one-on-one investor meetings at the Raymond James 2026 Biotech Innovation Symposium on April 14, 2026 in New York.
No company presentations are planned; management will discuss commercial products, and data and information from Akebia’s recent R&D Day showcasing its clinical-stage kidney disease pipeline.
Akebia Therapeutics (Nasdaq: AKBA) granted inducement stock options to 13 newly hired employees on March 31, 2026, covering an aggregate of 679,900 shares.
The options carry a $1.39 exercise price equal to the closing price on the grant date, vest over four years (25% at one year, then quarterly), and have a 10-year term under Akebia’s inducement award program in accordance with Nasdaq Listing Rule 5635(c)(4).
Akebia (Nasdaq: AKBA) appointed Philip J. Vickers, Ph.D., to its Board of Directors effective April 1, 2026, bringing over three decades of global biopharmaceutical leadership in R&D, translational science and corporate strategy. Akebia also announced the retirement of Steven C. Gilman, Ph.D., effective April 1, 2026.
Dr. Vickers has led biotech and pharma organizations including Solu Therapeutics, Faze Medicines, Northern Biologics and served as Global Head of R&D at Shire; he co-authored ~60 peer-reviewed publications and holds numerous patents.
Akebia Therapeutics (Nasdaq: AKBA) will host a virtual R&D Day on April 2, 2026 at 10:00 AM EDT to review its clinical-stage kidney disease pipeline.
Speakers include external scientific experts and management who will discuss praliciguat (Phase 2 FSGS), AKB-097 (Phase 2 planned H2 2026) and AKB-9090 (Phase 1 planned H1 2026), plus a live Q&A and webcast access via the investor website.
Akebia Therapeutics (NASDAQ: AKBA) said its CEO John P. Butler and CFO/Chief Business Officer Erik Ostrowski will participate in a Fireside Chat at the Leerink Partners 2026 Global Healthcare Conference on March 9, 2026 at 8:00 AM ET in Miami.
A webcast will be available via the company’s Investors website following the conference. The conference runs March 8-11, 2026.